A phase 2, randomized, double-blind study comparing Tremelimumab to placebo in Second- or third-line treatment of subjects with unresectable pleural or peritoneal malignant mesothelioma

Administered By

Awarded By

Contributors

Start/End

  • October 1, 2013 - April 21, 2017